Cancer drug shows promise for rare bleeding disorder

NCT ID NCT04404881

Ongoing Disease control Sponsor: Hanny Al-Samkari, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce chronic bleeding and iron-deficiency anemia in people with hereditary hemorrhagic telangiectasia (HHT). HHT causes abnormal blood vessels that bleed easily. The study involves 33 adults receiving intravenous bevacizumab over six months. The goal is to see if it lowers the need for blood transfusions and iron therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin)
What this could lead to: If it works, this could offer a new treatment to control bleeding and reduce the need for iron infusions or blood transfusions in people with HHT.
What could go wrong: This is a small phase 2 study with only 33 participants, so results may not apply to everyone. Bevacizumab can have side effects like high blood pressure or bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary hemorrhagic telangiectasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY HEMORRHAGIC TELANGIECTASIA

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.